| An Observational Multi-center Study to Evaluate Real-World Treatment Outcomes of Durvalumab-based Regimens in Hepatobiliary Cancers |
Ongoing |
Durvalumab |
4 |
D419CR00035 |
King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
| An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Marstacimab Prophylaxis in Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors |
Ongoing |
Marstacimab |
3 |
B7841007 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Fluid Management in Sickle Cell Disease Vaso-occlusive Crisis: Restrictive versus Liberal Strategies: A Randomized Controlled Trial (FLASC Trial) |
Ongoing |
Sodium Chloride / Lactated Ringers |
4 |
FLASC01 |
King Fahad University Hospital (Al-Khobar) |
| A Phase 3, Randomized, Double-Blind,Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease |
Ongoing |
Tulisokibart |
3 |
NCT0643080 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Hospital NG (Riyadh), King Saud University Medical City (Riyadh), King Abdullah Medical City Specialist Hospital (Makkah) |
| Prospective multi-country, real-world, multi-arm study of treatment PErsistence with RISankizumab in Psoriatic Arthritis |
Ongoing |
Risankizumab (Skyrizi®) |
4 |
P24-390 |
King Fahad Medical City (Riyadh) |
| An Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on Haemodialysis with Moderate-to-Severe Pruritus |
Ongoing |
Difelikefalin |
2 |
KOR-PED-202 |
King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Jeddah) |
| A Phase 2 / Phase 3, Multicenter, Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Adaptive Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents with Sickle Cell Disease during Vaso-Occlusive Crisis |
Ongoing |
CSL889 |
3 |
CSL889_2001 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Khalid University Hospital (Riyadh), Prince Mohammad Bin Naser Hospital (Jazan) |
| A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study To Assess The Efficacy And Safety of Induction and Maintenance Therapy with Ro7790121 in Patients with Moderately to Severely Active Crohn's Disease |
Ongoing |
Ro7790121 |
3 |
GA45331 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Saud Medical City (Riyadh) |
| Long-Term, Observational, Global Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies |
Ongoing |
Eculizumab |
3 |
ALXN-MG-50 |
Aseer Hospital (Abha) |
| A randomized, double-blinded placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of Efgartigimod PH20 SC Administered by prefilled syringe in adults participants with ocular MG |
Ongoing |
Efgartigimod |
3 |
ARGX-113-2315 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
